Skip to main content
Figure 2 | Virology Journal

Figure 2

From: Single dose of Glycoprotein K (gK)-deleted HSV-1 live-attenuated virus protects mice against lethal vaginal challenge with HSV-1 and HSV-2 and induces lasting T cell memory immune responses

Figure 2

Clinical disease score and pathology. (A) Clinical disease scores for vaccinated and mock vaccinated animals challenged with HSV-1 (McKrae) or HSV-2(G). Detailed clinical scores from seven days post challenge was recorded. Scores on a scale of 1–6 were assigned based on the following scheme: 0 = no disease, 1 = ruffled fur and generalized morbidity, 2 = mild genital erythema and edema, 3 = moderate genital inflammation, 4 = genital inflammation with purulent discharge, 5 = hind limb paralysis and 6 = death. Animals showing hind limb paralysis were immediately euthanized and scored as dead from the following day. In both HSV-1 (McKrae) and HSV-2(G) challenge groups, a significant difference was observed between mock vaccinated and vaccinated animals (p = 0.0005) using a two-tailed paired T-test. (B) HSV-1(McKrae) and HSV-2(G) infected mice exhibited similar disease progression and pathology. (a) Mock-infected vagina. (b) Mild disease symptoms included ruffled fur, hunching posture, inflammation and redness of vagina. (c) More serious manifestations included purulent vaginal discharge.

Back to article page